Patrick L Iversen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7232049/publications.pdf

Version: 2024-02-01

228 papers	10,063 citations	22099 59 h-index	48187 88 g-index
231 all docs	231 docs citations	231 times ranked	6453 citing authors

#	Article	IF	Citations
1	The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. PLoS Neglected Tropical Diseases, 2022, 16, e0010220.	1.3	11
2	Eastern equine encephalitis virus rapidly infects and disseminates in the brain and spinal cord of cynomolgus macaques following aerosol challenge. PLoS Neglected Tropical Diseases, 2022, 16, e0010081.	1.3	9
3	Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease. Scientific Reports, 2021, 11, 4722.	1.6	4
4	Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. Scientific Reports, 2021, 11, 19458.	1.6	9
5	Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962095491.	0.7	9
6	Recent successes in therapeutics for Ebola virus disease: no time for complacency. Lancet Infectious Diseases, The, 2020, 20, e231-e237.	4.6	42
7	Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field. Lancet Infectious Diseases, The, 2020, 20, 636-637.	4.6	1
8	Alternative Splicing in the Nuclear Receptor Superfamily Expands Gene Function to Refine Endo-Xenobiotic Metabolism. Drug Metabolism and Disposition, 2020, 48, 272-287.	1.7	10
9	Alternative splicing of the vitamin D receptor modulates target gene expression and promotes ligand-independent functions. Toxicology and Applied Pharmacology, 2019, 364, 55-67.	1.3	10
10	Safety, tolerability, and pharmacokinetics of radavirsen (AVIâ€7100), an antisense oligonucleotide targeting influenza a M1/M2 translation. British Journal of Clinical Pharmacology, 2018, 84, 25-34.	1.1	17
11	Chemicals in theÂEnvironment. , 2018, , 141-168.		0
12	Molecular Basis of Resilience. , 2018, , .		1
13	Eteplirsen. , 2018, , 257-279.		0
14	Regulating Resilience. , 2018, , 281-301.		0
15	Bacterial Infectious Disease Threat. , 2018, , 97-122.		0
16	Immune Defense. , 2018, , 169-193.		0
17	Active Oxygen Defenses. , 2018, , 195-222.		0
18	The Threat from Viruses. , 2018, , 45-76.		7

#	Article	IF	Citations
19	A k-mer based transcriptomics approach for antisense drug discovery targeting the Ewingâ€™s family of tumors. Oncotarget, 2018, 9, 30568-30586.	0.8	3
20	Analog Genetics. , 2018, , 223-255.		0
21	CURE 2000. , 2018, , 123-139.		0
22	Social Entropy. , 2018, , 19-44.		0
23	Nonlinear Anomalies. , 2018, , 77-95.		0
24	Alternative Splicing in the Cytochrome P450 Superfamily Expands Protein Diversity to Augment Gene Function and Redirect Human Drug Metabolism. Drug Metabolism and Disposition, 2017, 45, 375-389.	1.7	40
25	Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4213-4218.	3.3	94
26	Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques. PLoS Neglected Tropical Diseases, 2016, 10, e0004456.	1.3	24
27	A Single Phosphorodiamidate Morpholino Oligomer Targeting VP24 Protects Rhesus Monkeys against Lethal Ebola Virus Infection. MBio, 2015, 6, .	1.8	59
28	AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. New England Journal of Medicine, 2015, 373, 339-348.	13.9	50
29	Inhibition of hepatitis E virus replication by peptide-conjugated morpholino oligomers. Antiviral Research, 2015, 120, 134-139.	1.9	18
30	Experimental Therapeutics: Antisense and Gene Therapy Cardiovascular Drugs. , 2015, , 1067-1074.		0
31	Alternative Splice Forms of CTLA-4 Induced by Antisense Mediated Splice-Switching Influences Autoimmune Diabetes Susceptibility in NOD Mice. Nucleic Acid Therapeutics, 2014, 24, 114-126.	2.0	26
32	Induced IL-10 Splice Altering Approach to Antiviral Drug Discovery. Nucleic Acid Therapeutics, 2014, 24, 179-185.	2.0	12
33	Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies. Antimicrobial Agents and Chemotherapy, 2014, 58, 6639-6647.	1.4	73
34	Viral diversity and clonal evolution from unphased genomic data. BMC Genomics, 2014, 15, S17.	1.2	9
35	Benzimidazoisoquinolines: A New Class of Rapidly Metabolized Aryl Hydrocarbon Receptor (AhR) Ligands that Induce AhR-Dependent Tregs and Prevent Murine Graft-Versus-Host Disease. PLoS ONE, 2014, 9, e88726.	1.1	43
36	Experimental Therapeutics: Antisense and Gene Therapy Cardiovascular Drugs. , 2014, , 1-10.		0

#	Article	IF	Citations
37	Gene-Silencing Antisense Oligomers Inhibit Acinetobacter Growth In Vitro and In Vivo. Journal of Infectious Diseases, 2013, 208, 1553-1560.	1.9	64
38	Development of Novel Bioanalytical Methods to Determine the Effective Concentrations of Phosphorodiamidate Morpholino Oligomers in Tissues and Cells. BioResearch Open Access, 2013, 2, 61-66.	2.6	10
39	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses, 2012, 4, 2806-2830.	1.5	105
40	Lymphocytic Choriomeningitis Virus Infection in FVB Mouse Produces Hemorrhagic Disease. PLoS Pathogens, 2012, 8, e1003073.	2.1	17
41	Inhibition of p53 expression by peptide-conjugated phosphorodiamidate morpholino oligomers sensitizes human cancer cells to chemotherapeutic drugs. Oncogene, 2012, 31, 1024-1033.	2.6	15
42	Peptide Conjugated Phosphorodiamidate Morpholino Oligomers Increase Survival of Mice Challenged with AmesBacillus anthracis. Nucleic Acid Therapeutics, 2012, 22, 316-322.	2.0	11
43	Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. Cancer Gene Therapy, 2012, 19, 30-37.	2.2	11
44	Bacterial Resistance to Antisense Peptide Phosphorodiamidate Morpholino Oligomers. Antimicrobial Agents and Chemotherapy, 2012, 56, 6147-6153.	1.4	41
45	Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum. Human Molecular Genetics, 2011, 20, 3151-3160.	1.4	75
46	Treatment of highly pathogenic filovirus infections using advanced antisense technology. Retrovirology, 2010, 7, .	0.9	0
47	Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nature Medicine, 2010, 16, 991-994.	15.2	189
48	Antisense Phosphorodiamidate Morpholino Oligomers Targeted to an Essential Gene InhibitBurkholderia cepaciaComplex. Journal of Infectious Diseases, 2010, 201, 1822-1830.	1.9	75
49	Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo. Journal of Antimicrobial Chemotherapy, 2010, 65, 98-106.	1.3	42
50	Reduced Expression of CD45 Protein-tyrosine Phosphatase Provides Protection against Anthrax Pathogenesis. Journal of Biological Chemistry, 2009, 284, 12874-12885.	1.6	26
51	Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection. Antimicrobial Agents and Chemotherapy, 2009, 53, 2089-2099.	1.4	65
52	Inhibition of Intracellular Growth of Salmonella enterica Serovar Typhimurium in Tissue Culture by Antisense Peptide-Phosphorodiamidate Morpholino Oligomer. Antimicrobial Agents and Chemotherapy, 2009, 53, 3700-3704.	1.4	31
53	Variations in Amino Acid Composition of Antisense Peptide-Phosphorodiamidate Morpholino Oligomer Affect Potency against Escherichia coli In Vitro and In Vivo. Antimicrobial Agents and Chemotherapy, 2009, 53, 525-530.	1.4	65
54	Inhibition of HSV-1 ocular infection with morpholino oligomers targeting ICP0 and ICP27. Antiviral Research, 2009, 84, 131-141.	1.9	28

#	Article	IF	Citations
55	Byâ€passing the nonsense mutation in the 4^{CV} mouse model of muscular dystrophy by induced exon skipping. Journal of Gene Medicine, 2009, 11, 46-56.	1.4	44
56	Antisense Targeting of cFLIP Sensitizes Activated T Cells to Undergo Apoptosis and Desensitizes Responses to Contact Dermatitis. Journal of Investigative Dermatology, 2009, 129, 1945-1953.	0.3	6
57	Inhibition of measles virus infections in cell cultures by peptide-conjugated morpholino oligomers. Virus Research, 2009, 140, 49-56.	1.1	18
58	Cellular Uptake of Neutral Phosphorodiamidate Morpholino Oligomers. Current Pharmaceutical Biotechnology, 2009, 10, 579-588.	0.9	20
59	RNA-based therapeutics--from design to the clinic. Current Opinion in Molecular Therapeutics, 2009, 11, 107.	2.8	0
60	Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing. Current Opinion in Molecular Therapeutics, 2009, 11, 124-32.	2.8	12
61	Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers. Archives of Virology, 2008, 153, 929-937.	0.9	53
62	Cell penetrating peptide conjugates of steric block oligonucleotides. Advanced Drug Delivery Reviews, 2008, 60, 517-529.	6.6	168
63	West Nile virus genome cyclization and RNA replication require two pairs of long-distance RNA interactions. Virology, 2008, 373, 1-13.	1.1	88
64	Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology, 2008, 376, 357-370.	1.1	37
65	Inhibition of norovirus replication by morpholino oligomers targeting the 5â€²-end of the genome. Virology, 2008, 380, 328-337.	1.1	22
66	Peptide-conjugated morpholino oligomers inhibit porcine reproductive and respiratory syndrome virus replication. Antiviral Research, 2008, 77, 95-107.	1.9	65
67	c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. Lung Cancer, 2008, 60, 347-354.	0.9	44
68	T.P.2.10 Restoration of dystrophin expression in mdx mouse by peptide-conjugated antisense oligonucleotides. Neuromuscular Disorders, 2008, 18, 759.	0.3	0
69	Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Research, 2008, 36, 6343-6354.	6.5	79
70	A Morpholino Oligomer Targeting Highly Conserved Internal Ribosome Entry Site Sequence Is Able To Inhibit Multiple Species of Picornavirus. Antimicrobial Agents and Chemotherapy, 2008, 52, 1970-1981.	1.4	41
71	Blockade of viral interleukin-6 expression of Kaposi's sarcomaâ€“associated herpesvirus. Molecular Cancer Therapeutics, 2008, 7, 712-720.	1.9	26
72	Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus. Journal of General Virology, 2008, 89, 939-948.	1.3	57

#	Article	IF	Citations
73	Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14814-14819.	3.3	233
74	Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx Mice. Molecular Therapy, 2008, 16, 1624-1629.	3.7	230
75	Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus. Journal of Antimicrobial Chemotherapy, 2008, 62, 555-565.	1.3	59
76	Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline calicivirus infection. American Journal of Veterinary Research, 2008, 69, 23-32.	0.3	27
77	Inhibition of Respiratory Syncytial Virus Infections With Morpholino Oligomers in Cell Cultures and in Mice. Molecular Therapy, 2008, 16, 1120-1128.	3.7	51
78	Inhibition of Foot-and-Mouth Disease Virus Infections in Cell Cultures with Antisense Morpholino Oligomers. Journal of Virology, 2007, 81, 11669-11680.	1.5	34
79	Antiviral Effects of Antisense Morpholino Oligomers in Murine Coronavirus Infection Models. Journal of Virology, 2007, 81, 5637-5648.	1.5	82
80	In Vitro Resistance Selection and In Vivo Efficacy of Morpholino Oligomers against West Nile Virus. Antimicrobial Agents and Chemotherapy, 2007, 51, 2470-2482.	1.4	86
81	Involvement of Vacuolar Protein Sorting Pathway in Ebola Virus Release Independent of TSG101 Interaction. Journal of Infectious Diseases, 2007, 196, S264-S270.	1.9	40
82	Morpholino Oligomerâ€“Mediated Exon Skipping Averts the Onset of Dystrophic Pathology in the mdx Mouse. Molecular Therapy, 2007, 15, 1587-1592.	3.7	150
83	Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Research, 2007, 35, 5182-5191.	6.5	105
84	Cell-penetrating peptideâ€“morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular) Tj ETQq0 0 0 rgBT /Overlock 1 Transactions, 2007, 35, 826-828.	1.6	74
85	Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides. Biochemical Society Transactions, 2007, 35, 53-55.	1.6	51
86	Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochemical Society Transactions, 2007, 35, 775-779.	1.6	109
87	Pharmacokinetics, Biodistribution, Stability and Toxicity of a Cell-Penetrating Peptideâ^'Morpholino Oligomer Conjugate. Bioconjugate Chemistry, 2007, 18, 1325-1331.	1.8	169
88	Stability of Cell-Penetrating Peptideâ^'Morpholino Oligomer Conjugates in Human Serum and in Cells. Bioconjugate Chemistry, 2007, 18, 50-60.	1.8	158
89	Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Molecular Biology, 2007, 8, 57.	3.0	66
90	First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study. Cardiovascular Revascularization Medicine, 2007, 8, 230-235.	0.3	24

#	Article	IF	Citations
91	Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers. Antiviral Research, 2007, 73, 12-23.	1.9	47
92	Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. Journal of Immunological Methods, 2007, 325, 114-126.	0.6	28
93	Morpholinos. , 2007, , 565-582.		5
94	Antisense approach. , 2007, , 371-380.		0
95	VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice. Antimicrobial Agents and Chemotherapy, 2006, 50, 984-993.	1.4	119
96	Targeted vascular delivery of antisense molecules using intravenous microbubbles. Cardiovascular Revascularization Medicine, 2006, 7, 25-33.	0.3	23
97	Induced dystrophin exon skipping in human muscle explants. Neuromuscular Disorders, 2006, 16, 583-590.	0.3	63
98	Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genetic Vaccines and Therapy, 2006, 4, 3.	1.5	33
99	Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Therapy, 2006, 13, 1373-1381.	2.3	193
100	Suppression of porcine reproductive and respiratory syndrome virus replication by morpholino antisense oligomers. Veterinary Microbiology, 2006, 117, 117-129.	0.8	49
101	Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3â€² stemâ€“loop structure. Virology, 2006, 344, 439-452.	1.1	129
102	Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. Journal of Controlled Release, 2006, 116, 304-313.	4.8	180
103	Vesivirus viremia and seroprevalence in humans. Journal of Medical Virology, 2006, 78, 693-701.	2.5	33
104	Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology. Molecular Carcinogenesis, 2006, 45, 118-125.	1.3	7
105	Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers. PLoS Pathogens, 2006, 2, e1.	2.1	137
106	Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli. Journal of Antimicrobial Chemotherapy, 2006, 59, 66-73.	1.3	54
107	Inhibition of Multiple Subtypes of Influenza A Virus in Cell Cultures with Morpholino Oligomers. Antimicrobial Agents and Chemotherapy, 2006, 50, 3724-3733.	1.4	81
108	Inhibition of Coxsackievirus B3 in Cell Cultures and in Mice by Peptide-Conjugated Morpholino Oligomers Targeting the Internal Ribosome Entry Site. Journal of Virology, 2006, 80, 11510-11519.	1.5	64

#	Article	IF	Citations
109	Gene-Specific Effects of Antisense Phosphorodiamidate Morpholino Oligomer-Peptide Conjugates on Escherichia coli and Salmonella enterica Serovar Typhimurium in Pure Culture and inTissue Culture. Antimicrobial Agents and Chemotherapy, 2006, 50, 2789-2796.	1.4	58
110	Inhibition and Escape of SARS-CoV Treated with Antisense Morpholino Oligomers. Advances in Experimental Medicine and Biology, 2006, 581, 567-571.	0.8	11
111	Transdermal Delivery of Antisense Oligonucleotides. , 2005, 106, 255-270.		1
112	Local Application of Antisense for Prevention of Restenosis. , 2005, 106, 037-050.		3
113	Inhibition of infectious haematopoietic necrosis virus in cell cultures with peptide-conjugated morpholino oligomers. Journal of Fish Diseases, 2005, 28, 399-410.	0.9	20
114	Isolation and characterization of a new Vesivirus from rabbits. Virology, 2005, 337, 373-383.	1.1	24
115	Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model. Catheterization and Cardiovascular Interventions, 2005, 64, 389-394.	0.7	25
116	Inhibition of Flavivirus Infections by Antisense Oligomers Specifically Suppressing Viral Translation and RNA Replication. Journal of Virology, 2005, 79, 4599-4609.	1.5	151
117	Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis. Journal of Antimicrobial Chemotherapy, 2005, 55, 983-988.	1.3	52
118	Antiviral activity of morpholino oligomers designed to block various aspects of Equine arteritis virus amplification in cell culture. Journal of General Virology, 2005, 86, 3081-3090.	1.3	39
119	Antisense therapy for restenosis following percutaneous coronary intervention. Expert Opinion on Biological Therapy, 2005, 5, 79-89.	1.4	17
120	Inhibition of Dengue Virus Serotypes 1 to 4 in Vero Cell Cultures with Morpholino Oligomers. Journal of Virology, 2005, 79, 5116-5128.	1.5	108
121	Antisense Phosphorodiamidate Morpholino Oligomer Length and Target Position Effects on Gene-Specific Inhibition in Escherichia coli. Antimicrobial Agents and Chemotherapy, 2005, 49, 249-255.	1.4	51
122	Inhibition, Escape, and Attenuated Growth of Severe Acute Respiratory Syndrome Coronavirus Treated with Antisense Morpholino Oligomers. Journal of Virology, 2005, 79, 9665-9676.	1.5	102
123	Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Current Opinion in Pharmacology, 2005, 5, 550-555.	1.7	137
124	In vivo Bioavailability and Pharmacokinetics of a c-MYC Antisense Phosphorodiamidate Morpholino Oligomer, AVI-4126, in Solid Tumors. Clinical Cancer Research, 2005, 11, 3930-3938.	3.2	102
125	Arginine-Rich Peptide Conjugation to Morpholino Oligomers:â€‰ Effects on Antisense Activity and Specificity. Bioconjugate Chemistry, 2005, 16, 959-966.	1.8	54
126	An advanced antisense for local and stent based delivery for prevention of restenosis. , 2005, , 381-391.		0

#	Article	IF	Citations
127	Manipulation of zebrafish embryogenesis by phosphorodiamidate morpholino oligomers indicates minimal non-specific teratogenesis. Current Opinion in Molecular Therapeutics, 2005, 7, 104-8.	2.8	3
128	Antisense Morpholino-Oligomers Directed against the 5â€² End of the Genome Inhibit Coronavirus Proliferation and Growthâ€. Journal of Virology, 2004, 78, 5891-5899.	1.5	71
129	Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheterization and Cardiovascular Interventions, 2004, 61, 518-527.	0.7	37
130	Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin. International Journal of Pharmaceutics, 2004, 275, 217-226.	2.6	11
131	ANDROGEN RECEPTOR DOWN-REGULATION IN PROSTATE CANCER WITH PHOSPHORODIAMIDATE MORPHOLINO ANTISENSE OLIGOMERS. Journal of Urology, 2004, 172, 1140-1144.	0.2	32
132	Cellular Uptake of Antisense Morpholino Oligomers Conjugated to Arginine-Rich Peptides. Bioconjugate Chemistry, 2004, 15, 290-299.	1.8	184
133	Neutrally Charged Phosphorodiamidate Morpholino Antisense Oligomers: Uptake, Efficacy and Pharmacokinetics. Current Pharmaceutical Biotechnology, 2004, 5, 431-439.	0.9	68
134	X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Molecular Cancer Therapeutics, 2004, 3, 699-707.	1.9	97
135	Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model. Cardiovascular Radiation Medicine, 2003, 4, 152-159.	0.7	19
136	A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Therapy, 2003, 10, 823-832.	2.2	91
137	Inhibition of Gene Expression in Escherichia coli by Antisense Phosphorodiamidate Morpholino Oligomers. Antimicrobial Agents and Chemotherapy, 2003, 47, 3233-3239.	1.4	70
138	HIV Tat Peptide Enhances Cellular Delivery of Antisense Morpholino Oligomers. Oligonucleotides, 2003, 13, 31-43.	4.4	86
139	Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anti-Cancer Drugs, 2003, 14, 39-47.	0.7	56
140	Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clinical Cancer Research, 2003, 9, 2510-9.	3.2	98
141	Phosphorodiamidate Morpholino Antisense Oligomers Inhibit Expression of Human Cytochrome P450 3A4 and Alter Selected Drug Metabolism. Drug Metabolism and Disposition, 2002, 30, 757-762.	1.7	35
142	Responses of Human Cells to PAH-Induced DNA Damage. Polycyclic Aromatic Compounds, 2002, 22, 771-780.	1.4	2
143	Detection of vesicular exanthema of swine-like calicivirus in tissues from a naturally infected spontaneously aborted bovine fetus. Journal of the American Veterinary Medical Association, 2002, 220, 455-458.	0.2	16
144	Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. Journal of the American College of Cardiology, 2002, 39, 1686-1691.	1.2	61

#	Article	IF	Citations
145	Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model. Cardiovascular Radiation Medicine, 2002, 3, 26-30.	0.7	11
146	Bioavailability and Efficacy of Antisense Morpholino Oligomers Targeted to c-myc and Cytochrome P-450 3A2 Following Oral Administration in Rats. Journal of Pharmaceutical Sciences, 2002, 91, 1009-1018.	1.6	69
147	c-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney International, 2002, 61, S125-S131.	2.6	45
148	Inhibition of human chorionic gonadotropin ?-subunit modulates the mitogenic effect ofc-myc in human prostate cancer cells. Prostate, 2002, 53, 200-210.	1.2	39
149	Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharmaceutical Research, 2002, 19, 1465-1470.	1.7	20
150	Antisense treatment of caliciviridae: an emerging disease agent of animals and humans. Current Opinion in Molecular Therapeutics, 2002, 4, 177-84.	2.8	5
151	Oligonucleotide Enhanced Cytotoxicity of Idarubicin for Lymphoma Cells. Leukemia and Lymphoma, 2001, 42, 417-427.	0.6	7
152	Inhibition of carotid artery neointimal formation with intravenous microbubbles. Ultrasound in Medicine and Biology, 2001, 27, 259-265.	0.7	48
153	Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheterization and Cardiovascular Interventions, 2001, 54, 247-256.	0.7	28
154	Transdermal Delivery of Antisense Oligonucleotides Can Induce Changes in Gene ExpressionIn Vivo. Oligonucleotides, 2001, 11, 1-6.	4.4	23
155	Inhibition of Vesivirus Infections in Mammalian Tissue Culture with Antisense Morpholino Oligomers. Oligonucleotides, 2001, 11, 317-325.	4.4	32
156	Phosphorodiamidate Morpholino Oligomers. , 2001, , .		10
157	Transdermal delivery of antisense compounds. Advanced Drug Delivery Reviews, 2000, 44, 51-57.	6.6	30
158	Antiproliferative Effects of Steric Blocking Phosphorodiamidate Morpholino Antisense Agents Directed against c-myc. Oligonucleotides, 2000, 10, 163-176.	4.4	58
159	Pharmacokinetics and In Vivo Effects of a Six-Base Phosphorothioate Oligodeoxynucleotide with Anticancer and Hematopoietic Activities in Swine. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 205-214.	1.8	1
160	In VivoEvaluation of a Morpholino Antisense Oligomer Directed Against Tumor Necrosis Factor-Î±. Oligonucleotides, 2000, 10, 11-16.	4.4	33
161	Intracellular Delivery Strategies for Antisense Phosphorodiamidate Morpholino Oligomers. Oligonucleotides, 2000, 10, 263-274.	4.4	46
162	Evidence of Enhanced Iron Excretion During Systemic Phosphorothioate Oligodeoxynucleotide Treatment. Journal of Toxicology: Clinical Toxicology, 2000, 38, 383-387.	1.5	14

#	Article	IF	Citations
163	Evaluation of antisense mechanisms of action. Methods in Enzymology, 2000, 313, 135-143.	0.4	31
164	Photoactivation of Vascular iNOS and Elevation of cGMP In Vivo: Possible Mechanism for Photovasorelaxation and Inhibition of Restenosis in an Atherosclerotic Rabbit ModelÂ¶. Photochemistry and Photobiology, 2000, 72, 579.	1.3	11
165	Bolus Intravenous Injection of Phosphorothioate Oligonucleotides Causes Hypotension by Acting as Î±1-Adrenergic Receptor Antagonists. Toxicology and Applied Pharmacology, 1999, 160, 289-296.	1.3	29
166	The Cytotoxic Effects of Single-Stranded Telomere Mimics on OMA-BL1 Cells. Experimental Cell Research, 1999, 252, 41-49.	1.2	10
167	Lipoxygenase Inhibitors Abolish Proliferation of Human Pancreatic Cancer Cells. Biochemical and Biophysical Research Communications, 1999, 261, 218-223.	1.0	157
168	The suppression of metallothionein synthesis inhibits the growth of leukemia P388 cells. , 1999, , 613-617.		1
169	In vivo properties of an in situ forming gel for parenteral delivery of macromolecular drugs. Pharmaceutical Research, 1998, 15, 1189-1195.	1.7	14
170	Effects of Size and Sequence on the Iontophoretic Delivery of Oligonucleotidest. Journal of Pharmaceutical Sciences, 1998, 87, 49-52.	1.6	42
171	In vivo growth inhibition of leukemia P388 by Metallothionein-I antisense oligodeoxyribonucleotide. Journal of Trace Elements in Experimental Medicine, 1998, 11, 1-4.	0.8	3
172	An Experimental Model for Interpreting Percutaneous Penetration of Oligonucleotides that Incorporates the Role of Keratinoctyes11This manuscript has been assigned Journal Series Number 12144, Agricultural Research Division, University of Nebraska. Journal of Investigative Dermatology, 1998, 111, 1166-1171.	0.3	9
173	Manipulation of Metallothionein Expression in the Regenerating Rat Liver Using Antisense Oligonucleotides. Biochemical and Biophysical Research Communications, 1998, 246, 711-718.	1.0	19
174	Tumor cell growth is inhibited by suppressing metallothionein-I synthesis. Cancer Letters, 1997, 116, 145-149.	3.2	19
175	Ex Vivo Treatment of Bone Marrow with Phosphorothioate Oligonucleotide OL(l)p53 for Autologous Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Stem Cells and Development, 1997, 6, 441-446.	1.0	28
176	Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies. Journal of Pharmacological and Toxicological Methods, 1997, 37, 229-235.	0.3	9
177	A Hexameric Phosphorothioate Oligonucleotide Telomerase Inhibitor Arrests Growth of Burkitt's Lymphoma Cellsin Vitroandin Vivo. Toxicology and Applied Pharmacology, 1997, 144, 189-197.	1.3	75
178	Qualitative and quantitative measurements of oligonucleotides in gene therapy: Part I in vitro models. Journal of Pharmaceutical and Biomedical Analysis, 1997, 15, 857-873.	1.4	8
179	Qualitative and quantitative measurements of oligonucleotides in gene therapy: Part II in vivo models. Journal of Pharmaceutical and Biomedical Analysis, 1997, 15, 1127-1135.	1.4	7
180	Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.. Journal of Clinical Oncology, 1996, 14, 1320-1326.	0.8	146

#	Article	IF	Citations
181	Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon-exposed sonicated dextrose albumin microbubbles.. Journal of Ultrasound in Medicine, 1996, 15, 577-584.	0.8	102
182	Iontophoretic delivery of a telomeric oligonucleotide. Pharmaceutical Research, 1996, 13, 851-854.	1.7	40
183	Continuous Infusion of Antisense Phosphorothioate Therapeutics. , 1996, 1, 201-212.		1
184	Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. Journal of Clinical Laboratory Analysis, 1995, 9, 129-137.	0.9	114
185	Prenatal and presymptomatic diagnosis of the marfan syndrome using fluorescence pcr and an automated sequencer. Prenatal Diagnosis, 1995, 15, 499-507.	1.1	7
186	Anin vitro model for endothelial permeability: Assessment of monolayer integrity. In Vitro Cellular and Developmental Biology - Animal, 1995, 31, 846-852.	0.7	42
187	Reaction between Metabolically Activated Acetaminophen and Phosphorothioate Oligonucleotides. Toxicology and Applied Pharmacology, 1995, 133, 53-63.	1.3	15
188	In Vivo Modulation of the Rat Cytochrome P450 1A1 by Double-Stranded Phosphorothioate Oligodeoxynucleotides. Toxicology and Applied Pharmacology, 1995, 135, 179-184.	1.3	3
189	Cholesteryl-Conjugated Phosphorothioate Oligodeoxynucleotides Modulate CYP2B1 ExpressionIn Vivo. Journal of Drug Targeting, 1995, 2, 477-485.	2.1	38
190	Preparation of Oligomeric 2â€²-Deoxy-5-Fluorouridylate of Defined Length and Backbone Composition: A Novel Pro-Drug form of the Potent Anti-Cancer Drug 2â€²-Deoxy-5-Fluorouridylate. Nucleosides & Nucleotides, 1995, 14, 243-253.	0.5	9
191	Effects ofBCR-ABLAntisense Oligonucleotides (AS-ODN) on Human Chronic Myeloid Leukemic Cells: AS-ODN as Effective Purging Agents. Leukemia and Lymphoma, 1995, 20, 67-76.	0.6	20
192	Expression and regulation of brain metallothionein. Neurochemistry International, 1995, 27, 1-22.	1.9	146
193	Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin. Antisense Research and Development, 1995, 5, 131-139.	3.3	106
194	Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicology Letters, 1995, 82-83, 425-430.	0.4	25
195	Patterns of Cellular Uptake and Effects on Cell Survival Using Antimetallothionein Oligodeoxyribonucleotide Conjugates in vitro. NeuroSignals, 1994, 3, 140-149.	0.5	2
196	Selective Cytotoxicity to Human Leukemic Myeloblasts Produced by Oligodeoxyribonucleotide Phosphorothioates Complementary to p53 Nucleotide Sequences. Leukemia and Lymphoma, 1994, 12, 223-231.	0.6	48
197	Oligonucleotides in the treatment of leukemia. Hematological Oncology, 1994, 12, 9-14.	0.8	26
198	Metallothionein in carcinogenesis and cancer chemotherapy. General Pharmacology, 1994, 25, 1297-1310.	0.7	39

#	Article	IF	Citations
199	Involvement of cytochrome P450 2E1-like isoform in the activation of N-nitrosobis(2-oxopropyl)amine in the rat nasal mucosa. European Journal of Cancer Part B, Oral Oncology, 1994, 30, 179-185.	0.9	9
200	Antisense Oligonucleotide of c-<i>myc</i> Discriminates between Zinc- and Dexamethasone-Induced Synthesis of Metallothionem. Pharmacology, 1994, 48, 119-126.	0.9	10
201	HIV-1revAntisense Phosphorothioate Oligonucleotide Binding to Human Mononuclear Cells Is Cell Type Specific and Inducible. Antisense Research and Development, 1994, 4, 285-289.	3.3	8
202	Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide against rev from Human Immunodeficiency Virus Type 1 in the Adult Male Rat Following Single Injections and Continuous Infusion. Antisense Research and Development, 1994, 4, 43-52.	3.3	89
203	Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial. Antisense Research and Development, 1993, 3, 383-390.	3.3	138
204	Cellular Uptake and Subcellular Distribution of Phosphorothioate Oligonucleotides into Cultured Cells. Antisense Research and Development, 1992, 2, 211-222.	3.3	148
205	Antisense Oligonucleotide-Mediated Inhibition of Metallothionein Protein Synthesis in Neuroblastoma IMR 32 and Chang Liver Cells in Culture. NeuroSignals, 1992, 1, 57-64.	0.5	14
206	Synthetic Antisense Oligonucleotide Probes the Essentiality of Metallothionein Gene. NeuroSignals, 1992, 1, 293-299.	0.5	9
207	Binding of Antisense Phosphorothioate Oligonucleotides to Murine Lymphocytes Is Lineage Specific and Inducible. Antisense Research and Development, 1992, 2, 223-233.	3.3	27
208	Systemic Human Antisense Therapy Begins. Antisense Research and Development, 1992, 2, 109-110.	3.3	54
209	Induction of cytochromes P450IA1 and P450IA2 as determined by solution hybridization. Biochemical Pharmacology, 1991, 41, 1719-1723.	2.0	9
210	Preparation of 35S-labeled polyphosphorothioate oligodeoxyribonucleotides by use of hydrogen phosphonate chemistry. Analytical Biochemistry, 1990, 188, 11-16.	1.1	34
211	The mechanism of inhibition of cytochrome P450IIE1 by dihydrocapsaicin. Bioorganic Chemistry, 1990, 18, 185-198.	2.0	36
212	Regulation of zinc metallothionein II mRNA level in rat brain. Neurochemistry International, 1990, 17, 441-447.	1.9	21
213	Inhibition of Human Immunodeficiency Virus Type 1-mediated Cytopathic Effects by Poly(L-lysine)-conjugated Synthetic Antisense Oligodeoxyribonucleotides. Journal of General Virology, 1989, 70, 2673-2682.	1.3	83
214	Health and Medical Care in Ethiopia. New England Journal of Medicine, 1989, 320, 1149-1150.	13.9	0
215	Chromatographic and spectral investigations on the in vivo metabolites of 6-nitrobenzo[a]pyrene. Journal of Chromatography A, 1988, 450, 325-336.	1.8	3
216	Synergy of phenobarbital and 3-methylcholanthrene in â€œsuperinductionâ€•of cytochrome P-450c mRNA but not enzyme activity. Biochemical Pharmacology, 1987, 36, 3399-3403.	2.0	10

#	Article	IF	Citations
217	Structural details of the human cytochrome P-450c gene. Archives of Biochemistry and Biophysics, 1987, 256, 397-401.	1.4	12
218	The molecular biology of the polycyclic aromatic hydrocarbon inducible cytochrome P-450; the past is prologue. BioEssays, 1986, 4, 15-19.	1.2	7
219	Microsomal cytochrome P-450 â€œHandprintsâ€: Five fractions from anion-exchange high-pressure liquid chromatography provide a rapid preliminary screen for selectivity in the induction and destruction of rat hepatic cytochrome P-450 subpopulations. Toxicology and Applied Pharmacology, 1985, 78, 1-9.	1.3	17
220	Selective changes in cytochrome P-450 and UDP-glucuronosyltransferase subpopulations following partial hepatectomy in rats. Toxicology and Applied Pharmacology, 1985, 78, 10-18.	1.3	26
221	Gene structure and nucleotide sequence for rat cytochrome P-450c. Archives of Biochemistry and Biophysics, 1985, 237, 465-476.	1.4	61
222	Preparation and partial characterization of highly purified primary cultures of neurons and non-neuronal (glial) cells from embryonic chick cerebral hemispheres and several other regions of the nervous system. Developmental Brain Research, 1982, 3, 529-545.	2.1	28
223	Neuronal stimulation of non-neuronal (glial) cell proliferation: Lack of specificity between different regions of the nervous system. Developmental Brain Research, 1982, 3, 547-555.	2.1	16
224	Regulation of the proliferation of embryonic chick leptomeningeal cells in vitro by both contact inhibition and co-culture with CNS neurons. Journal of Neuroscience Research, 1982, 8, 523-534.	1.3	3
225	Characterization of a variety of standard collagen substrates: Ultrastructure, uniformity, and capacity to bind and promote growth of neurons. In Vitro, 1981, 17, 540-552.	1.2	19
226	Effects of millimeter-wave radiation on monolayer cell cultures. II. Scanning and transmission electron microscopy. Bioelectromagnetics, 1981, 2, 141-150.	0.9	14
227	The turnover of tRNAs microinjected into animal cells. Nucleic Acids Research, 1978, 5, 3715-3730.	6.5	21
228	Functional Activation of Autologous Human Diabetic Stem Cells for Cell Therapy. , 0, , .		0